Press Release

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com

CORCEPT THERAPEUTICS FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING

MENLO PARK, Calif., February 10, 2004 -- Corcept Therapeutics Incorporated today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering by the Company and a selling stockholder of shares of the Company's common stock.
The offering will be managed by Thomas Weisel Partners LLC, Piper Jaffray and Legg Mason Wood Walker Incorporated. The number of shares to be offered and the price range for the offering have not been determined. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Thomas Weisel Partners LLC at One Montgomery Street, Suite 3700, San Francisco, CA 94104.

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product candidate, Corlux™, is currently in Phase III clinical trials for the treatment of psychotic major depression.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

###